BR9509889A - Composto composição farmacêutica e processos para inibir beta-lactamases e para aumentar a atrividade biológica de um antibiótico do tipo beta-lactama - Google Patents

Composto composição farmacêutica e processos para inibir beta-lactamases e para aumentar a atrividade biológica de um antibiótico do tipo beta-lactama

Info

Publication number
BR9509889A
BR9509889A BR9509889A BR9509889A BR9509889A BR 9509889 A BR9509889 A BR 9509889A BR 9509889 A BR9509889 A BR 9509889A BR 9509889 A BR9509889 A BR 9509889A BR 9509889 A BR9509889 A BR 9509889A
Authority
BR
Brazil
Prior art keywords
beta
lactamases
attractiveness
biological
processes
Prior art date
Application number
BR9509889A
Other languages
English (en)
Inventor
John D Buynak
Brian Bachmann
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of BR9509889A publication Critical patent/BR9509889A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9509889A 1994-12-09 1995-12-11 Composto composição farmacêutica e processos para inibir beta-lactamases e para aumentar a atrividade biológica de um antibiótico do tipo beta-lactama BR9509889A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/354,850 US5629306A (en) 1994-12-09 1994-12-09 7-alkylidene cephalosporanic acid derivatives and methods of using the same
PCT/US1995/015608 WO1996017849A1 (en) 1994-12-09 1995-12-11 7-alkylidene cephalosporanic acid derivatives and methods of using the same

Publications (1)

Publication Number Publication Date
BR9509889A true BR9509889A (pt) 1997-12-30

Family

ID=23395164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509889A BR9509889A (pt) 1994-12-09 1995-12-11 Composto composição farmacêutica e processos para inibir beta-lactamases e para aumentar a atrividade biológica de um antibiótico do tipo beta-lactama

Country Status (11)

Country Link
US (3) US5629306A (pt)
EP (1) EP0796262B1 (pt)
JP (1) JP3241737B2 (pt)
AT (1) ATE263173T1 (pt)
AU (1) AU4290796A (pt)
BR (1) BR9509889A (pt)
CA (1) CA2206699C (pt)
DE (1) DE69532820T2 (pt)
ES (1) ES2218557T3 (pt)
PT (1) PT796262E (pt)
WO (1) WO1996017849A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629306A (en) * 1994-12-09 1997-05-13 Research Corporation Technologies, Inc. 7-alkylidene cephalosporanic acid derivatives and methods of using the same
US5760027A (en) * 1996-12-06 1998-06-02 Research Corporation Technologies, Inc. Use of 7-alkylidene cephalosporins to inhibit elastase activity
DE69805975T2 (de) 1997-12-29 2002-12-19 Res Corp Technologies Inc 2-beta-substituierte-6-alkylidenpenizillansäure-derivate als beta-laktamase inhibitoren
ATE242250T1 (de) 1997-12-29 2003-06-15 Res Corp Technologies Inc Verfahren zur herstellung von alpha-oxolactamen
JP2002542249A (ja) * 1999-04-15 2002-12-10 リサーチ コーポレイション テクノロジーズ，インコーポレイティド β−ラクタマーゼ阻害化合物
US6407091B1 (en) * 1999-04-15 2002-06-18 Research Corporation Technologies, Inc. β-lactamase inhibiting compounds
EP1359153B1 (en) * 1999-04-15 2006-06-21 Research Corporation Technologies, Inc Beta-lactamase inhibiting compounds
JP2005502687A (ja) * 2001-07-24 2005-01-27 アラムクス エルエルシー β−ラクタマーゼ阻害剤としての７−アルキリデン−３−置換型−３−セフェム−４−カルボキシラート
JP2005525399A (ja) * 2002-04-04 2005-08-25 アラムクス エルエルシー セリンおよびメタロ−β−ラクタマーゼの阻害剤
KR101403164B1 (ko) * 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
AU2012233003B2 (en) * 2005-12-07 2014-12-18 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150156A (en) * 1975-11-21 1979-04-17 Merck & Co., Inc. 7-(Substituted methyl)-3-(substituted thio)-cephalosporins, derivatives and pharmaceutical compositions containing them
EP0041768B1 (en) * 1980-04-24 1987-11-11 Beecham Group Plc Beta-lactam compounds, their preparation and use
US4459405A (en) * 1982-11-16 1984-07-10 Eli Lilly And Company Desacetylcephalosporin sulfones
EP0120613A1 (en) * 1983-03-02 1984-10-03 Beecham Group Plc Penem derivatives and precursors
US4547371A (en) * 1983-04-18 1985-10-15 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
US5132301A (en) * 1983-05-02 1992-07-21 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
US4637999A (en) 1983-05-02 1987-01-20 Merck & Co., Inc. Substituted cephalosporins as anti-inflammatory and antidegenerative agents
GB8518421D0 (en) * 1985-07-22 1985-08-29 Beecham Group Plc Compounds
GB8808701D0 (en) 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
GB8811388D0 (en) * 1988-05-13 1988-06-15 Erba Carlo Spa 1,1-dioxo-cephem-4-carbothiolic acid derivatives
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US4992541A (en) 1989-08-01 1991-02-12 Merck & Co., Inc. Process for the preparation of 1,1-dioxo-7-substituted cephems
US5264429A (en) 1989-10-06 1993-11-23 Synphar Laboratories, Inc. 2-spirocyclopropyl cephalosporin sulfone derivatives
GB8928373D0 (en) * 1989-12-15 1990-02-21 Erba Carlo Spa Beta-lactam derivatives
US5126446A (en) * 1991-01-04 1992-06-30 Eli Lilly And Company Process for 3-exomethylenecepham sulfoxide esters
US5258377A (en) 1991-04-08 1993-11-02 Taiho Pharmaceutical Co., Ltd. 2-spirocyclopropyl 4-acylcephems
US5446037A (en) * 1991-12-05 1995-08-29 Synphar Laboratories, Inc. 2-[(substituted) methylene]cephalosporin sulfones as antiinflammatory, antidegenerative and antithrombin agents
US5629306A (en) * 1994-12-09 1997-05-13 Research Corporation Technologies, Inc. 7-alkylidene cephalosporanic acid derivatives and methods of using the same
US5597817A (en) 1994-12-09 1997-01-28 Southern Methodist University 7-vinylidene cephalosporins and methods of using the same

Also Published As

Publication number Publication date
US20020025954A1 (en) 2002-02-28
JP3241737B2 (ja) 2001-12-25
WO1996017849A1 (en) 1996-06-13
EP0796262A4 (en) 1998-03-25
ATE263173T1 (de) 2004-04-15
JPH10510265A (ja) 1998-10-06
US5629306A (en) 1997-05-13
DE69532820T2 (de) 2005-01-13
DE69532820D1 (de) 2004-05-06
US6599892B2 (en) 2003-07-29
CA2206699A1 (en) 1996-06-13
EP0796262B1 (en) 2004-03-31
EP0796262A1 (en) 1997-09-24
ES2218557T3 (es) 2004-11-16
PT796262E (pt) 2004-08-31
CA2206699C (en) 2007-03-20
AU4290796A (en) 1996-06-26
US6303592B1 (en) 2001-10-16

Similar Documents

Publication Publication Date Title
FI942423A0 (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
CA2030433A1 (en) New isoquinoline- carboxamide amino acid derivatives useful for treatment of viral diseases
GR3026699T3 (en) Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same.
SE8602723D0 (sv) Thiazoles, their production and pharmaceutical compositions containing them
AU2829292A (en) Saccharin derivative proteolytic enzyme inhibitors
BR9509889A (pt) Composto composição farmacêutica e processos para inibir beta-lactamases e para aumentar a atrividade biológica de um antibiótico do tipo beta-lactama
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
ATE246192T1 (de) Ethyliden-derivate tricyclyscher carbapenems
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
KR970702723A (ko) 베타-락탐 항생 물질과 조합하여 베타-락타마아제를 억제하는 페넴을 함유하는 약제학적 제형물 및 박테리아 감염의 치료에서 상기 제형물을 사용하는 방법(pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections)
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
IT1216104B (it) Peptidi ad attivita' farmaceutica.
AU5890986A (en) Derivatives of penem
TR199900141T2 (xx) Bunama tedavisi ve/veya profilaksisi i�in form�lasyon.
IT1216103B (it) Peptidi ad attivita' farmaceutica.
CO4700467A1 (es) Derivados de cephalosporin fluoroquinolonatos y composicio- nes farmaceuticas que los contengan

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements